Table 2.
Baseline Prevalence of Resistance to Reverse-Transcriptase Inhibitors
| Genotypic resistance data | N (%) |
|---|---|
| Previous genotypic data analysis | 196 (100.0) |
| Resistance to at least one: | |
| NRTI | 11 (5.6) |
| NNRTI | 8 (4.1) |
| RPV | 2 (1.0) |
| Other | 6 (3.1) |
| Resistance to both NRTI + NNRTI | 11 (5.6) |
| NRTI RAMs | |
| None | 174 (88.8) |
| M184V | 14 (7.1) |
| K65R + M184V | 3 (1.5) |
| Other | 5 (2.6) |
| NNRTI RAMs | |
| None | 177 (90.3) |
| RPV-specific | 8 (4.1) |
| H221Y | 1 (0.5) |
| E138A | 2 (1.0) |
| Y181C pathwaya | 5 (2.6) |
| K103N without RPV RAM | 10 (5.1) |
| Other (179E + 190A) | 1 (0.5) |
Abbreviations: NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; RAMs, resistance-associated mutations; RPV, rilpivirine.
a Associated with others mutations (101E; 179DV + 103N; 101KE + 190A; 103N + 179VF; 221HL).